JP2005501110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501110A5 JP2005501110A5 JP2003522564A JP2003522564A JP2005501110A5 JP 2005501110 A5 JP2005501110 A5 JP 2005501110A5 JP 2003522564 A JP2003522564 A JP 2003522564A JP 2003522564 A JP2003522564 A JP 2003522564A JP 2005501110 A5 JP2005501110 A5 JP 2005501110A5
- Authority
- JP
- Japan
- Prior art keywords
- hdl
- use according
- administered
- ischemia
- reperfusion injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 15
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001840 cholesterol esters Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- -1 for example Proteins 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31360501P | 2001-08-20 | 2001-08-20 | |
| EP01120026A EP1285662A1 (en) | 2001-08-20 | 2001-08-20 | Reconstituted HDL for the treatment of stroke and ischemic conditions |
| PCT/EP2002/009294 WO2003018047A2 (en) | 2001-08-20 | 2002-08-20 | Hdl for the treatment of stroke and other ischemic conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005501110A JP2005501110A (ja) | 2005-01-13 |
| JP2005501110A5 true JP2005501110A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
| JP4284177B2 JP4284177B2 (ja) | 2009-06-24 |
Family
ID=26076691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522564A Expired - Fee Related JP4284177B2 (ja) | 2001-08-20 | 2002-08-20 | 脳卒中および他の虚血性症状の治療用ｈｄｌ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040266660A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1425031B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4284177B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE396736T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002340825B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2457840C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60226881D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2304452T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003018047A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200401360B (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1668645A (zh) * | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2007000924A1 (ja) * | 2005-06-28 | 2007-01-04 | Osaka University | プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法 |
| US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
| AU2007200908B2 (en) * | 2007-03-01 | 2012-08-16 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| JP5601750B2 (ja) * | 2007-03-01 | 2014-10-08 | シーエスエル、リミテッド | 糖尿病患者の内皮機能異常の治療 |
| WO2010151096A1 (en) | 2009-06-25 | 2010-12-29 | Tetra, Sia | Therapeutic combinations of nicotinic acid and meldonium |
| WO2011006994A1 (en) | 2009-07-16 | 2011-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hdl comprising a therapeutic agent and use in therapy |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| US12419839B2 (en) | 2009-10-09 | 2025-09-23 | Signablok, Inc. | Methods and compositions for targeted delivery of protein fragments |
| US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
| CN105288589A (zh) | 2011-02-07 | 2016-02-03 | 塞勒尼斯医疗控股公司 | 脂蛋白复合物及其制备和用途 |
| EP2688584A4 (en) * | 2011-03-25 | 2015-05-20 | Univ Columbia | PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| ES2984285T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Cargómeros |
| ES2984286T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| WO2021191266A1 (en) | 2020-03-25 | 2021-09-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hdl for the treatment of lung infections |
| WO2021209823A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein- based complexes |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| US20230372532A1 (en) * | 2020-10-05 | 2023-11-23 | Northwestern University | Targeted ph sensitive liposomes |
| US20240215570A1 (en) | 2021-04-15 | 2024-07-04 | Abionyx Pharma Sa | Use of lipid binding protein-based complexes in organ preservation solutions |
| WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| AU2023284357A1 (en) | 2022-06-10 | 2025-01-23 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
| IL322074A (en) | 2023-01-13 | 2025-09-01 | Abionyx Pharma Sa | Treatment using a lipid-binding protein molecule |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| GB9919713D0 (en) * | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AUPQ429399A0 (en) | 1999-11-26 | 1999-12-23 | Heart Research Institute, The | Oxidized apolipoproteins and methods of use |
-
2002
- 2002-08-20 EP EP02774525A patent/EP1425031B8/en not_active Expired - Lifetime
- 2002-08-20 US US10/487,224 patent/US20040266660A1/en not_active Abandoned
- 2002-08-20 JP JP2003522564A patent/JP4284177B2/ja not_active Expired - Fee Related
- 2002-08-20 ES ES02774525T patent/ES2304452T3/es not_active Expired - Lifetime
- 2002-08-20 AU AU2002340825A patent/AU2002340825B2/en not_active Ceased
- 2002-08-20 WO PCT/EP2002/009294 patent/WO2003018047A2/en not_active Ceased
- 2002-08-20 AT AT02774525T patent/ATE396736T1/de active
- 2002-08-20 DE DE60226881T patent/DE60226881D1/de not_active Expired - Lifetime
- 2002-08-20 CA CA2457840A patent/CA2457840C/en not_active Expired - Fee Related
-
2004
- 2004-02-19 ZA ZA2004/01360A patent/ZA200401360B/en unknown
-
2007
- 2007-05-04 US US11/744,780 patent/US7491693B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501110A5 (cg-RX-API-DMAC7.html) | ||
| CA2457840A1 (en) | Hdl for the treatment of stroke and other ischemic conditions | |
| ES2200171T3 (es) | Combinaciones de vasopresina y agentes adrenergeticos para el tratamiento del paro cardiaco. | |
| CN101287457B (zh) | Treprostinil用于治疗神经性糖尿病的足部溃疡的用途 | |
| JP2007514750A5 (cg-RX-API-DMAC7.html) | ||
| JP2002528502A5 (cg-RX-API-DMAC7.html) | ||
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| AU2003282464B2 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
| JP2002523437A5 (cg-RX-API-DMAC7.html) | ||
| JP2002530353A5 (cg-RX-API-DMAC7.html) | ||
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| CA2931567A1 (en) | Sprayable aqueous composition comprising glyceryl trinitrate | |
| AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| Komatsu et al. | Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion-and arachidonic acid-induced stroke models in rats | |
| CN103664936A (zh) | 一类治疗创伤性脑损伤疾病的化合物及其用途 | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| JP2008505087A5 (cg-RX-API-DMAC7.html) | ||
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins | |
| JP2002529515A5 (cg-RX-API-DMAC7.html) | ||
| RU2200026C2 (ru) | Антиангинальное средство | |
| JP4965791B2 (ja) | 敗血症性ショックの治療方法 | |
| JPH027293B2 (cg-RX-API-DMAC7.html) |